Crossject Société Anonyme (EPA:ALCJ)

France flag France · Delayed Price · Currency is EUR
1.950
+0.010 (0.52%)
Apr 28, 2026, 5:35 PM CET
121.59%
Market Cap 102.84M
Revenue (ttm) 2.57M
Net Income (ttm) -10.37M
Shares Out 52.74M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 4.33
Dividend n/a
Ex-Dividend Date n/a
Volume 61,559
Average Volume 222,620
Open 1.940
Previous Close 1.940
Day's Range 1.930 - 1.964
52-Week Range 0.877 - 2.695
Beta 0.52
RSI 42.90
Earnings Date Jun 24, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev... [Read more]

Sector Healthcare
Founded 2001
Employees 103
Stock Exchange Euronext Paris
Ticker Symbol ALCJ
Full Company Profile

Financial Performance

In 2025, Crossject Société Anonyme's revenue was 2.57 million, a decrease of -37.64% compared to the previous year's 4.12 million. Losses were -10.37 million, -18.98% less than in 2024.

Financial Statements

News

There is no news available yet.